We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
|Numero di pagine||1|
|Rivista||THE LANCET ONCOLOGY|
|Stato di pubblicazione||Published - 2020|
All Science Journal Classification (ASJC) codes